Characterisation of a divergent progenitor cell sub-populations in human osteoarthritic cartilage: the role of telomere erosion and replicative senescence

In recent years it has become increasingly clear that articular cartilage harbours a viable pool ofprogenitor cells and interest has focussed on their role during development and disease. Analysis ofprogenitor numbers using fluorescence-activated sorting techniques has resulted in wide-rangingestimates, which may be the result of context-dependent expression of cell surface markers. Wehave used a colony-forming assay to reliably determine chondroprogenitor numbers in normal andosteoarthritic cartilage where we observed a 2-fold increase in diseased tissue (P < 0.0001). Intriguingly,cell kinetic analysis of clonal isolates derived from single and multiple donors of osteoarthritic cartilagerevealed the presence of a divergent progenitor subpopulation characterised by an early senescentphenotype. Divergent sub-populations displayed increased senescence-associated β–galactosidaseactivity, lower average telomere lengths but retained the capacity to undergo multi-lineagedifferentiation. Osteoarthritis is an age-related disease and cellular senescence is predicted to be asignificant component of the pathological process. This study shows that although early senescenceis an inherent property of a subset of activated progenitors, there is also a pool of progenitors withextended viability and regenerative potential residing within osteoarthritic cartilage

Evaluation of Cellular Phenotypes Implicated in Immunopathogenesis and Monitoring Immune Reconstitution Inflammatory Syndrome in HIV/Leprosy Cases

BACKGROUND: It is now evident that HAART-associated immunological improvement often leads to a variety of new clinical manifestations, collectively termed immune reconstitution inflammatory syndrome, or IRIS. This phenomenon has already been described in cases of HIV coinfection with Mycobacterium leprae, most of them belonging to the tuberculoid spectrum of leprosy disease, as observed in leprosy reversal reaction (RR). However, the events related to the pathogenesis of this association need to be clarified. This study investigated the immunological profile of HIV/leprosy patients, with special attention to the cellular activation status, to better understand the mechanisms related to IRIS/RR immunopathogenesis, identifying any potential biomarkers for IRIS/RR intercurrence. METHODS/PRINCIPAL FINDINGS: Eighty-five individuals were assessed in this study: HIV/leprosy and HIV-monoinfected patients, grouped according to HIV-viral load levels, leprosy patients without HIV coinfection, and healthy controls. Phenotypes were evaluated by flow cytometry for T cell subsets and immune differentiation/activation markers. As expected, absolute counts of the CD4+ and CD8+ T cells from the HIV-infected individuals changed in relation to those of the leprosy patients and controls. However, there were no significant differences among the groups, whether in the expression of cellular differentiation phenotypes or cellular activation, as reflected by the expression of CD38 and HLA-DR. Six HIV/leprosy patients identified as IRIS/RR were analyzed during IRIS/RR episodes and after prednisone treatment. These patients presented high cellular activation levels regarding the expression of CD38 in CD8+ cells T during IRIS/RR (median: 77,15%), dropping significantly (p<0,05) during post-IRIS/RR moments (median: 29,7%). Furthermore, an increase of cellular activation seems to occur prior to IRIS/RR. CONCLUSION/SIGNIFICANCE: These data suggest CD38 expression in CD8+ T cells interesting tool identifying HIV/leprosy individuals at risk for IRIS/RR. So, a comparative investigation to leprosy patients at RR should be conducted

Acetaminophen Modulates the Transcriptional Response to Recombinant Interferon-β

BACKGROUND: Recombinant interferon treatment can result in several common side effects including fever and injection-site pain. Patients are often advised to use acetaminophen or other over-the-counter pain medications as needed. Little is known regarding the transcriptional changes induced by such co-administration. METHODOLOGY/PRINCIPAL FINDINGS: We tested whether the administration of acetaminophen causes a change in the response normally induced by interferon-beta treatment. CD-1 mice were administered acetaminophen (APAP), interferon-beta (IFN-beta) or a combination of IFN-beta+APAP and liver and serum samples were collected for analysis. Differential gene expression was determined using an Agilent 22 k whole mouse genome microarray. Data were analyzed by several methods including Gene Ontology term clustering and Gene Set Enrichment Analysis. We observed a significant change in the transcription profile of hepatic cells when APAP was co-administered with IFN-beta. These transcriptional changes included a marked up-regulation of genes involved in signal transduction and cell differentiation and down-regulation of genes involved in cellular metabolism, trafficking and the IkappaBK/NF-kappaB cascade. Additionally, we observed a large decrease in the expression of several IFN-induced genes including Ifit-3, Isg-15, Oasl1, Zbp1 and predicted gene EG634650 at both early and late time points. CONCLUSIONS/SIGNIFICANCE: A significant change in the transcriptional response was observed following co-administration of IFN-beta+APAP relative to IFN-beta treatment alone. These results suggest that administration of acetaminophen has the potential to modify the efficacy of IFN-beta treatment

Microclimate monitoring of Ariadne's house (Pompeii, Italy) for preventive conservation of fresco paintings

Background: Ariadne's house, located at the city center of ancient Pompeii, is of great archaeological value due to the fresco paintings decorating several rooms. In order to assess the risks for long-term conservation affecting the valuable mural paintings, 26 temperature data-loggers and 26 relative humidity data-loggers were located in four rooms of the house for the monitoring of ambient conditions. Results: Data recorded during 372 days were analyzed by means of graphical descriptive methods and analysis of variance (ANOVA). Results revealed an effect of the roof type and number of walls of the room. Excessive temperatures were observed during the summer in rooms covered with transparent roofs, and corrective actions were taken. Moreover, higher humidity values were recorded by sensors on the floor level. Conclusions: The present work provides guidelines about the type, number, calibration and position of thermohygrometric sensors recommended for the microclimate monitoring of mural paintings in outdoor or semi-confined environments. © 2012 Merello et al.; licensee Chemistry Central Ltd.This work was partially supported by the Spanish Government (Ministerio de Ciencia e Innovacion) under projects HAR2010-21944-C02-01 and HAR2010-21944-C02-02.Merello Giménez, P.; García Diego, FJ.; Zarzo Castelló, M. (2012). Microclimate monitoring of Ariadne's house (Pompeii, Italy) for preventive conservation of fresco paintings. Chemistry Central Journal. 6:145-161. https://doi.org/10.1186/1752-153X-6-145S1451616Ribera A, Olcina M, Ballester C: Pompeya Bajo Pompeya, las Excavaciones en la Casa de Ariadna. Valencia: Fundación MARQ; 2007.World Monuments Fund: World Monuments Watch: 100 Most Endangered Sites. New York: World Monuments Fund; 1996.Anter KF: Colours in Pompeiian cityscape: Adding pieces to the puzzle. Color Res Appl 2006,31(4):331–340.Harris J: Protecting Pompeii and the Italian heritage in 2012. http://www.i-italy.org/bloggers/18935/protecting-pompeii-and-italian-heritage-2012Augusti S: La Tecnica Dell’antica Pittura Parietale Pompeiana. Napoli: Gaetano Macchiaroli Editore; 1950.Miriello D, Barca D, Bloise A, Ciarallo A, Crisci GM, De Rose T, Gattuso C, Gazineo F, La Russa MF: Characterisation of archaeological mortars from Pompeii (Campania, Italy) and identification of construction phases by compositional data analysis. J Arch Sci 2010, 37:2207–2223.Castriota M, Cosco V, Barone T, De Santo G, Carafa P, Cazzanelli E: Micro-Raman characterizations of Pompei’s mortars. J Raman Spectrosc 2008,39(2):295–301.Maguregui M, Knuutinen U, Castro K, Madariaga JM: Raman spectroscopy as a tool to diagnose the impact and conservation state of Pompeian second and fourth style wall paintings exposed to diverse environments (House of Marcus Lucretius). J Raman Spectrosc 2010,41(11):1400–1409.Genestar C, Pons C, Más A: Analytical characterisation of ancient mortars from the archaeological Roman city of Pollentia (Balearic Islands, Spain). Anal Chim Acta 2006, 557:373–379.Duran A, Perez-Maqueda LA, Poyato J, Perez-Rodriguez JL: A thermal study approach to roman age wall painting mortars. J Therm Anal Calorim 2010,99(3):803–809.Pérez MC, García Diego F-J, Merello P, D’Antoni P, Fernández Navajas A, Ribera Lacomba A, Ferrazza L, Pérez Miralles J, Baró JL, Merce P, D’Antoni H, Curiel Esparza J: Ariadne’s house (Pompeii, Italy) wall paintings: a multidisciplinary study of its present state focused on a future restoration and preventive conservation. Mater Constr in pressBernardi A: Microclimate in the British Museum. London. Museum Manag Curat 1990, 9:169–182.Bernardi A, Camuffo D: Microclimate in the Chiericati Palace Municipal Museum. Vicenza. Museum Manag Curat 1995, 14:5–18.Camuffo D, Bernardi A, Sturaro G, Valentino A: The microclimate inside the Pollaiolo and Botticelli rooms in the Uffizi Gallery. Florence. J Cult Herit 2002, 3:155–161.La Gennusa M, Rizzo G, Scaccianoce G, Nicoletti F: Control of indoor environments in heritage buildings: Experimental measurements in an old Italian museum and proposal of a methodology. J Cult Herit 2005,6(2):147–155.Camuffo D, Sturaro G, Valentino A: Thermodynamic exchanges between the external boundary layer and the indoor microclimate at the Basilica of Santa Maria Maggiore, Rome, Italy: the problem of conservation of ancient works of art. Bound Lay Meteorol 1999, 92:243–262.Tabunschikov Y, Brodatch M: Indoor air climate requirements for Russian churches and cathedrals. Indoor Air 2004,14(Suppl 7):168–174.Loupa G, Charpantidou E, Kioutsioukis I, Rapsomanikis S: Indoor microclimate, ozone and nitrogen oxides in two medieval churches in Cyprus. Atmos Environ 2006, 40:7457–7466.Vuerich E, Malaspina F, Barazutti M, Georgiadis T, Nardino M: Indoor measurements of microclimate variables and ozone in the church of San Vincenzo (Monastery of Bassano Romano – Italy): a pilot study. Microchem J 2008, 88:218–223.García-Diego F-J, Zarzo M: Microclimate monitoring by multivariate statistical control: the renaissance frescoes of the cathedral of valencia (Spain). J Cult Herit 2010,11(3):339–344.Zarzo M, Fernández-Navajas A, García-Diego F-J: Long-term monitoring of fresco paintings in the Cathedral of Valencia (Spain) through humidity and temperature sensors in various locations for preventive conservation. Sensors 2011,11(9):8685–8710.Maekawa S, Lambert F, Meyer J: Environmental monitoring at Tiwanaku. Mater Res Soc Symp Proc 1995, 352:885–892.Lillie M, Smith R, Reed J, Inglis R: Southwest Scottish Crannogs: using in situ studies to assess preservation in wetland archaeological contexts. J Archaeol Sci 2008,35(7):1886–1900.Verdecchia F, Zoccatelli C, Norelli E, Miandro R: Integrated monitoring network for surface deformation in Capo Colonna archaeological area, Crotone. Italy. IAHS-AISH P 2010, 339:345–351.Nava S, Becherini F, Bernardi A, Bonazza A, Chiari M, García-Orellana I, Lucarelli F, Ludwig N, Migliori A, Sabbioni C, Udisti R, Valli G, Vecchi R: An integrated approach to assess air pollution threats to cultural heritage in a semi-confined environment: the case study of Michelozzo’s Courtyard in Florence (Italy). Sci Total Environ 2010,408(6):1403–1413.Hygrochron Temperature/Humidity Logger iButton with 8KB Data-Log Memory. Maxim Integrated Products. http://datasheets.maxim-ic.com/en/ds/DS1923.pdfTemperature Logger iButton with 8KB Data-Log Memory. Maxim Integrated Products. http://datasheets.maxim-ic.com/en/ds/DS1922L-DS1922T.pdfVisco G, Plattner SH, Fortini P, Di Giovanni S, Sammartino MP: Microclimate monitoring in the Carcer Tullianum: temporal and spatial correlation and gradients evidenced by multivariate analysis; first campaign. Chem Cent J 2012,6(Suppl 2):S11.UNI 10829: Works of Art of Historical Importance. Ambient Conditions for the Conservation. Measurement and Analysis. Milano: UNI Ente Nazionale Italiano di Unificazione; 1999.DM 10/2001: Atto di Indirizzo sui Criteri Tecnico-scientifici e Sugli Standard di Funzionamento e Sviluppo dei Musei. Ministero per i Beni e le Attività Culturali. Gazzeta Ufficiale della Repubblica Italiana (Official Bulletin of Italian Republica), Rome (Italy); 2001. DL 112/1998 art. 150 comma 6Camuffo D: Microclimate for Cultural Heritage. Amsterdam: Elsevier Science; 1998.ASTM E 104–02: Standard Practice for Maintaining Constant Relative Humidity by Means of Aqueous Solutions. West Conshohocken, PA: ASTM Intl; 2012.Statgraphics Software. http://www.statgraphics.ne

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction &gt;0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years